Device Trial Radar · NCT05394662
Safety and Effectiveness of Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Aug 11, 2022
Primary completion
Apr 23, 2025
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- Rejoni Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine whether intrauterine instillation of Juveena hydrogel following adhesiogenic hysteroscopic procedures (TCGP + Juveena) can safely and effectively reduce the incidence and severity of intrauterine adhesions (IUA) compared to TCGP alone.
Conditions
- Intrauterine Adhesion
Interventions
Juveena Hydrogel SystemDevice
Application of a novel hydrogel immediately following the transcervical procedure
Transcervical Gynecologic Procedures (TCGP)Procedure
Hysteroscopic adhesiolysis or hysteroscopic myomectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom From Intrauterine Adhesions (IUA)Time frame: 8 weeks
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Arizona Gynecology Consultants
Phoenix, Arizona
UCSF Center for Reproductive Health
San Francisco, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.